The Use of Indocyanine Green Near-infrared Fluorescence for Bowel Perfusion Quantitative Assessment in Order to Prevent Anastomotic Leakage in Colorectal Surgery

NCT ID: NCT06845306

Last Updated: 2025-02-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

1268 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-06-01

Study Completion Date

2026-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Anastomotic leakage (AL) is a serious complication after surgery for colon cancer, leading to a significant increase in mortality.Intraoperative fluorescence imaging using indocyanine green has proven to be a feasible and reproducible technique for real-time perfusion assessment.

An increasing number of studies are being published on the use of indocyanine green (ICG) fluorescence imaging in colorectal cancer surgery, showing promising results.

Therefore, we propose conducting a multicenter, randomized controlled trial to investigate the potential use of quantitative assessment of near-infrared fluorescence imaging with indocyanine green (ICG) to prevent anastomotic leaks during colorectal surgery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colo-rectal Cancer Colonic Neoplasms Malignant

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

multicentre randomized controlled trial
Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants
Intraoperative imaging cannot blind the surgeon. The patient is only blinded prior to surgery.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

The ICG group

The ICG group, where, before creating the anastomosis, intestinal blood flow will be assessed using quantitative near-infrared fluorescence imaging using indocyanine green.

Group Type ACTIVE_COMPARATOR

ICG-guided bowel perfusion assessment

Intervention Type DRUG

ICG will be injected before anastomosis is created, to quantitatively assess the perfusion status of the bowel.

The control group

The control group, where before the creation of the anastomosis, the intestinal blood flow will not be assessed.

Group Type PLACEBO_COMPARATOR

Conventional Bowel Anastomosis group

Intervention Type OTHER

conventional perfusion assessment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ICG-guided bowel perfusion assessment

ICG will be injected before anastomosis is created, to quantitatively assess the perfusion status of the bowel.

Intervention Type DRUG

Conventional Bowel Anastomosis group

conventional perfusion assessment

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged over 18 years old
* ECOG status 0-2
* Written informed consent
* histologically confirmed neoplasms malignant of the colon (caecum, ascending, transverse, descending, sigmoid)
* Scheduled for colorectal resection with primary anastomosis

Exclusion Criteria

* Pregnancy or breast feeding
* Colon obstruction, perforation or bleeding complicating the tumor
* Medical contraindications for surgical treatment
* Known allergy or history of adverse reaction to ICG, iodine or iodine dyes
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Vadim Kuznetsov

NETWORK

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Vadim Kuznetsov

The doctor is a researcher

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Victor Kashchenko, Doctor of Medical Sciences

Role: STUDY_DIRECTOR

BELOOSTROV Clinic of High Technologies

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

BELOOSTROV Clinic of High Technologies

Vsevolozhsk District, Leningradskaya Oblast', Russia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Russia

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Vadim Kuznetsov

Role: CONTACT

+79043302184

Timur Lankov

Role: CONTACT

+79046077444

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Vadim Kuznetsov

Role: primary

+79043302184

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TBELOSTROVCOFHICG

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.